Inferra AI / Company / BDX
Becton Dickinson
BDX · Health Care
Last earnings Aug 6, 2026
Key results
Revenuequarter
$ 4,714
Second Quarter Fiscal 2026 Operating Results Three Months Ended March 31, Reported Change Foreign Currency Neutral Change 1 (Millions of dollars, except per share amounts) 2026 2025 Revenues $ 4,714 $ 4,480 5.2 % 2.6 % Reported Diluted Earnings per Share $ (0.13) $ 0.55 (123.6) % (130.9) % Adjusted Diluted Earnings per Share 1 $ 2.90 $ 2.79 3.9 % 1.1 % 1 Represents a non-GAAP financial measure refer to reconciliations of non-GAAP financial measures in the attached financial tables.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
Reported EPSquarter
$ 0.55
Second Quarter Fiscal 2026 Operating Results Three Months Ended March 31, Reported Change Foreign Currency Neutral Change 1 (Millions of dollars, except per share amounts) 2026 2025 Revenues $ 4,714 $ 4,480 5.2 % 2.6 % Reported Diluted Earnings per Share $ (0.13) $ 0.55 (123.6) % (130.9) % Adjusted Diluted Earnings per Share 1 $ 2.90 $ 2.79 3.9 % 1.1 % 1 Represents a non-GAAP financial measure refer to reconciliations of non-GAAP financial measures in the attached financial tables.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
Adjusted EPSquarter
$ 2.90
Second Quarter Fiscal 2026 Operating Results Three Months Ended March 31, Reported Change Foreign Currency Neutral Change 1 (Millions of dollars, except per share amounts) 2026 2025 Revenues $ 4,714 $ 4,480 5.2 % 2.6 % Reported Diluted Earnings per Share $ (0.13) $ 0.55 (123.6) % (130.9) % Adjusted Diluted Earnings per Share 1 $ 2.90 $ 2.79 3.9 % 1.1 % 1 Represents a non-GAAP financial measure refer to reconciliations of non-GAAP financial measures in the attached financial tables.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
Total revenuequarter
5.1 %
Geographic Results Revenues (Millions of dollars) Three Months Ended March 31, Reported Change Foreign Currency Neutral Change 1 2026 2025 United States $ 2,917 $ 2,776 5.1 % 5.1 % International $ 1,797 $ 1,704 5.5 % (1.4) % Total Revenues $ 4,714 $ 4,480 5.2 % 2.6 % 1 Represents a non-GAAP financial measure refer to reconciliations of non-GAAP financial measures in the attached financial tables.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
Page 2 Segment Results Revenues (Millions of dollars) Three Months Ended March 31, Reported Change Foreign Currency Neutral Change 1 2026 2025 Medical Essentials 2 $ 1,647 $ 1,573 4.7 % 1.7 % Connected Care 2 $ 1,120 $ 1,068 4.9 % 3.2 % BioPharma Systems 2 $ 590 $ 575 2.5 % (1.8) % Interventional 2 $ 1,357 $ 1,264 7.3 % 5.3 % Total Revenues $ 4,714 $ 4,480 5.2 % 2.6 % 1 Represents a non-GAAP financial measure refer to reconciliations of non-GAAP financial measures in the attached financial tables.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
AI analysis
Q2 FY2026 · reported May 7, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q2 FY2026 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $ 4,714 | — | — |
| Reported EPS | $ 0.55 | — | — |
| Adjusted EPS | $ 2.90 | — | — |
| Total revenue | 5.1 % | — | — |
Guidance · company-stated
Direction: Raised
“com BD Reports Second Quarter Fiscal 2026 Financial Results Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXN GAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectively Executed a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt in the quarter Company reaffirms revenue growth guidance, raises full-year adjusted diluted EPS guidance 1 FRANKLIN LAKES, NJ (May 7, 2026) - BD (Becton, Dickinson and Company) (NYSE BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.”
“Based on our first half performance and improved visibility into the balance of the year, we are raising our full year adjusted EPS guidance and reaffirming our revenue growth expectations.”
Classified from the release's primary full-year outlook statement.
Capital allocation
com BD Reports Second Quarter Fiscal 2026 Financial Results Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXN GAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectively Executed a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt in the quarter Company reaffirms revenue growth guidance, raises full-year adjusted diluted EPS guidance 1 FRANKLIN LAKES, NJ (May 7, 2026) - BD (Becton, Dickinson and Company) (NYSE BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.
Event summary
Becton Dickinson Q2 FY2026 — Second Quarter Fiscal 2026 Operating Results Three Months Ended March 31, Reported Change Foreign Currency Neutral Change 1 (Millions of dollars, except per share amounts) 2026 2025 Revenues $ 4,714 $…
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “com BD Reports Second Quarter Fiscal 2026 Financial Results Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXN GAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectively Executed a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt in the quarter Company reaffirms revenue growth guidance, raises full-year adjusted diluted EPS guidance 1 FRANKLIN LAKES, NJ (May 7, 2026) - BD (Becton, Dickinson and Company) (NYSE BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.”
Revenue: “Based on our first half performance and improved visibility into the balance of the year, we are raising our full year adjusted EPS guidance and reaffirming our revenue growth expectations.”
Revenue — Raised (“increased”)
“com BD Reports Second Quarter Fiscal 2026 Financial Results Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXN GAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectively Executed a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt in the quarter Company reaffirms revenue growth guidance, raises full-year adjusted diluted EPS guidance 1 FRANKLIN LAKES, NJ (May 7, 2026) - BD (Becton, Dickinson and Company) (NYSE BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.”
Revenue — Raised (“raising”)
“Based on our first half performance and improved visibility into the balance of the year, we are raising our full year adjusted EPS guidance and reaffirming our revenue growth expectations.”
Classified from the release's primary full-year outlook statement.
Capital allocation
com BD Reports Second Quarter Fiscal 2026 Financial Results Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXN GAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectively Executed a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt in the quarter Company reaffirms revenue growth guidance, raises full-year adjusted diluted EPS guidance 1 FRANKLIN LAKES, NJ (May 7, 2026) - BD (Becton, Dickinson and Company) (NYSE BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
Adjusted diluted earnings per share includes adjustments for the impact of purchase accounting adjustments, integration and restructuring costs, transaction costs, separation-related costs, certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, certain pension settlement costs, and the impact of the extinguishment of debt.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
BD used $ 2 billion of the proceeds to repurchase BD common shares under the terms of an accelerated share repurchase program, which is further discussed in Note 4, and the remaining $ 2 billion was used for debt repayments, which is further discussed in Note 14.
SEC original ↗Becton Dickinson — 10-Q Quarterly report10-QAug 6, 2026
(b) Amounts recorded to Treasury stock include excise tax on share repurchases.
SEC original ↗Becton Dickinson — 10-Q Quarterly report10-QAug 6, 2026
Share Repurchases In the first quarter of fiscal year 2026, the Company repurchased 1.315 million shares of its common stock for total consideration of $ 250 million through open market repurchases.
SEC original ↗Becton Dickinson — 10-Q Quarterly report10-QAug 6, 2026
In the second quarter of fiscal year 2026, the Company executed two accelerated share repurchase ( ASR ) agreements concurrently to repurchase its common stock using a portion of the proceeds from the Transaction as further discussed in Note 2.
SEC original ↗Becton Dickinson — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
We remain focused on disciplined execution of our New BD strategy, including advancing our commercial and innovation initiatives across key growth platforms, expanding margins, and delivering on our capital allocation framework, all to drive sustainable long term shareholder value.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
Connected Care Announced a strategic partnership with Wellstar Health System to advance patient care and safety with medication management powered by AI, building a more connected approach from the pharmacy to the bedside by integrating the BD Pyxis Pro and BD Alaris Platforms to give clinicians clearer insight, greater accuracy and simple automation.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
BD named a Top 100 Global Innovator by LexisNexis , reflecting the strength of BD's innovation engine and contributions to sustainable growth, margin expansion and competitive advantage.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
Restructuring costs for the three months ended March 31, 2026 reflect non-cash asset impairment charges of $450 million across all reportable segments based upon the Company's commitment to exit certain operational activities and projects which no longer align with and facilitate its current operational strategy, Excellence Unleashed.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
Restructuring costs for the six months ended March 31, 2026 reflect non-cash asset impairment charges of $450 million across all reportable segments based upon the Company's commitment to exit certain operational activities and projects which no longer align with and facilitate its current operational strategy, Excellence Unleashed.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
Risks & headwinds
All such statements are based upon current expectations and assumptions of BD and involve a number of business risks and uncertainties.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
These factors include, but are not limited to, risks relating to macroeconomic conditions and their impact on our operations and healthcare spending generally, including any impact related to the imposition of (and changing policies around) new and existing tariffs enacted by the U.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
governments), or our ability to mitigate the impact of such tariffs, including developments regarding refunds of certain tariffs import or export licensing requirements and other governmental restrictions reductions in U.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
Tariff commentary is based on tariff policies in effect as of May 6, 2026.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
International trade policies, trade restrictions and tariffs (and related countermeasures and developments regarding refunds of certain tariffs) are rapidly evolving and there can be no assurance as to how the landscape may change and what the ultimate impact on our guidance and results of operations will be.
SEC original ↗Becton Dickinson — Earnings release (8-K exhibit)EX-99May 7, 2026
Legal Proceedings 52 Item 1A.
SEC original ↗Becton Dickinson — 10-Q Quarterly report10-QAug 6, 2026
Earnings deck slides
0 decks with slide viewBecton Dickinson — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
71 documents- Q2 2026
- 10-QBDX
Aug 6, 2026
- 8-KBDX
Aug 6, 2026
- 8-KBDX
Jul 22, 2026
- Q1 2026
- 8-KBDX
May 29, 2026
- 8-KBDX
May 20, 2026
- 8-KBDX
May 12, 2026
- 10-QBDX
May 7, 2026
- 8-K/ABDX
May 7, 2026
- 8-KBDX
May 7, 2026
- 8-KBDX
Apr 29, 2026
- 8-KBDX
Apr 9, 2026
- 8-KBDX
Apr 2, 2026
- Q4 2025
- 8-KBDX
Feb 25, 2026
- EX-99BDX
Feb 25, 2026
- EX-99BDX
Feb 25, 2026
- 8-KBDX
Feb 10, 2026
- EX-99BDX
Feb 10, 2026
- 10-QBDX
Feb 9, 2026
- 8-KBDX
Feb 9, 2026
- 8-KBDX
Feb 9, 2026
- EX-99BDX
Feb 9, 2026
- 8-KBDX
Feb 5, 2026
- 8-KBDX
Feb 5, 2026
- EX-99BDX
Feb 5, 2026
- 8-KBDX
Jan 30, 2026
- 8-KBDX
Jan 6, 2026
- Q3 2025
- 8-K/ABDX
Dec 1, 2025
- 10-KBDX
Nov 25, 2025
- 8-KBDX
Nov 17, 2025
- 8-KBDX
Nov 6, 2025
- 8-KBDX
Oct 15, 2025
- EX-99BDX
Oct 15, 2025
- Q2 2025
- 8-KBDX
Sep 18, 2025
- 10-QBDX
Aug 7, 2025
- 8-KBDX
Aug 7, 2025
- 8-KBDX
Jul 14, 2025
- 8-KBDX
Jul 14, 2025
- Q1 2025
- 8-KBDX
Jun 16, 2025
- 8-KBDX
May 2, 2025
- 8-KBDX
May 1, 2025
- 10-QBDX
May 1, 2025
- Q4 2024
- 8-KBDX
Mar 27, 2025
- 10-QBDX
Feb 6, 2025
- 8-KBDX
Feb 5, 2025
- EX-99BDX
Feb 5, 2025
- 8-KBDX
Jan 31, 2025
- 8-KBDX
Jan 10, 2025
- EX-99BDX
Jan 10, 2025
- Q3 2024
- 10-KBDX
Nov 27, 2024
- 8-KBDX
Nov 7, 2024
- 8-KBDX
Oct 2, 2024
- EX-99BDX
Oct 2, 2024
- Q2 2024
- 8-KBDX
Aug 30, 2024
- 8-KBDX
Aug 1, 2024
- 10-QBDX
Aug 1, 2024
- 8-KBDX
Jul 12, 2024
- Q1 2024
- 8-KBDX
Jun 7, 2024
- 8-KBDX
Jun 3, 2024
- EX-99BDX
Jun 3, 2024
- 8-KBDX
May 2, 2024
- 10-QBDX
May 2, 2024
- Q4 2023
- 8-KBDX
Feb 27, 2024
- EX-99BDX
Feb 27, 2024
- 8-KBDX
Feb 8, 2024
- 8-KBDX
Feb 6, 2024
- 8-KBDX
Feb 1, 2024
- 10-QBDX
Feb 1, 2024
- 8-KBDX
Jan 26, 2024
- Q3 2023
- 8-KBDX
Dec 21, 2023
- 8-KBDX
Nov 27, 2023
- 10-KBDX
Nov 21, 2023
Earnings releases
20 documentsPresentations
1 document- Q1 2024
- BDXDeck
Transcripts
0 documentsNo transcripts for Becton Dickinson are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.